{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:31:10Z","timestamp":1788258670240,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This mini\u2010review explores glucocorticoids, mycophenolate mofetil (MMF), and hydroxychloroquine (HCQ) in IgA nephropathy (IgAN). It discusses conflicting findings from pivotal trials like TESTING and STOP\u2010IgAN regarding glucocorticoid efficacy, emphasizing reduced\u2010dose protocols as potentially safer options. MMF's effectiveness varies among populations, demonstrating promise in Chinese cohorts but yielding inconclusive results elsewhere. HCQ shows potential in reducing proteinuria, with ongoing trials investigating its long\u2010term benefits.<\/jats:p>","DOI":"10.1111\/nep.14369","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:19:10Z","timestamp":1721294350000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in <scp>IgA<\/scp> nephropathy, an update of current clinical trials"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-4723","authenticated-orcid":false,"given":"Pei","family":"Chen","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine Peking University First Hospital  Beijing China"},{"name":"Institute of Nephrology Peking University  Beijing China"},{"name":"Key Laboratory of Renal Disease Ministry of Health of China  Beijing China"},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University) Ministry of Education  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine Peking University First Hospital  Beijing China"},{"name":"Institute of Nephrology Peking University  Beijing China"},{"name":"Key Laboratory of Renal Disease Ministry of Health of China  Beijing China"},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University) Ministry of Education  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070697"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp356"},{"issue":"12","key":"e_1_2_6_8_1","first-page":"796","article-title":"A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy","volume":"82","author":"Chen X","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00588.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh974"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.499"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.013"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.11.027"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000702"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.08.022"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.01.026"},{"key":"e_1_2_6_18_1","article-title":"Long\u2010term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single\u2010center experience","author":"Tang C","year":"2022","journal-title":"J Nephrol"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.14369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:30:50Z","timestamp":1727415050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.14369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":17,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/nep.14369"],"URL":"https:\/\/doi.org\/10.1111\/nep.14369","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"2024-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}